PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Telitacicept Add-On Boosts Renal Response in Proliferative Lupus Nephritis

telitaciceptbelimumabBAFF/APRIL inhibitorTACI-Fc fusion proteinproliferative lupus nephritislupus nephritissystemic lupus erythematosusglucocorticoid sparingretrospective cohortIPTWinduction therapyrheumatologynephrology Rheumatology / Immunology
Also in Nephrology

Background Information

Telitacicept enhances renal response in lupus nephritis.

Telitacicept combined with standard care improves renal outcomes for patients with proliferative lupus nephritis, potentially enhancing current treatment protocols. At week 24, patients on telitacicept had higher complete renal response (67.9% vs 39.3%, p=0.004) and partial renal response rates (83.9% vs 67.9%, p=0.023) compared to controls. This study indicates that telitacicept may offer a more effective induction therapy for proliferative lupus nephritis, although these findings require validation in broader clinical trials. Telitacicept significantly boosts renal response rates in proliferative lupus nephritis, offering potential for reduced glucocorticoid use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Tian T, Zhang A, Liu X, Wu P, Li N, Zeng L, Liu J, Qin L, Zeng J

Citation: Tian T, Zhang A, Liu X, et al. Efficacy and safety of telitacicept combined with standard of care in patients with proliferative lupus nephritis: a real-world retrospective study. Lupus science & medicine. 2026;13(2). doi:10.1136/lupus-2026-002191

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.